Concarlo

Brooklyn, US · 3 known investors

Concarlo Therapeutics develops cancer therapeutics that target CDK4/6-driven cell proliferation and CDK2-driven resistance, focusing on improving outcomes for cancer patients through novel approaches in p27 biology.

Biotechin /concarlo-therapeutics-llc @concarlo760

Founders & leadership

LisaMarie CaseyPresident and Manager

Stacy BlainFounder and CEO

Investors · 3

BioAdvanceConshohocken · $500K – $1.5M

Creative Destruction Lab (CDL)Toronto · $50K – $250K

Raptor GroupMiami Beachvia Jim Pallotta · inferred

Reported raises · per SEC filings

Form D private placements

▶$450KraisedMar 2017 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

LisaMarie CaseyExecutive Officer, Director

Offering amount: $1.2M
Amount sold: $450K
Minimum investment: $25K
First sale: Mar 2017
Incorporated: Limited Liability Company, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.